Date: 2015-06-16
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Apexigen (USA - CA)
Product: APX005M
Action
mechanism: monoclonal antibody. APX005M is an immuno-activating monoclonal antibody targeting CD40, a receptor that plays a central role in the regulation of antigen presentation functions and tumor-specific T cell response.
Disease: solid tumors
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: The study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M. (NCT02482168)
Latest
news: * On June 16, 2015, Apexigen, a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced the initiation of a Phase 1 clinical trial of APX005M, the company\'s lead proprietary anticancer program. The trial is a Phase 1, open-label dose-escalation study of APX005M in adults with solid tumors that is intended to establish the maximum tolerated dose, the pharmacokinetic profile and the overall safety and tolerability of APX005M. The study will also seek evidence of activation of the immune system in response to treatment and preliminary assessment of clinical response.
